Roche spotlights Perjeta's staying power with 10-year breast cancer survival results
After a decade of follow-up, Roche's Perjeta, Herceptin and chemotherapy regimen cut the risk of death by 17% in patients with early-stage HER2-positive breast cancer.
After a decade of follow-up, Roche's Perjeta, Herceptin and chemotherapy regimen cut the risk of death by 17% in patients with early-stage HER2-positive breast cancer.
